C11orf21 (C-15): sc-241998



The Power to Question

BACKGROUND

With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and disease-association dense chromosome. The chromosome 11 encoded Atm gene is important for regulation of cell cycle arrest and apoptosis following double strand DNA breaks. Atm mutation leads to the disorder known as ataxia-telangiectasia. The blood disorders Sickle cell anemia and β thalassemia are caused by HBB gene mutations. Wilms' tumors, WAGR syndrome and Denys-Drash syndrome are associated with mutations of the WT1 gene. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are also associated with defects in chromosome 11. The C11orf21 gene product has been provisionally designated C11orf21 pending further characterization.

REFERENCES

- Grossfeld, P.D., et al. 2004. The 11q terminal deletion disorder: a prospective study of 110 cases. Am. J. Med. Genet. A 129: 51-61.
- Loussouarn, G., et al. 2006. KCNQ1 K+ channel-mediated cardiac channelopathies. Methods Mol. Biol. 337: 167-183.
- Taylor, T.D., et al. 2006. Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature 440: 497-500.
- Zehelein, J., et al. 2006. Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. J. Biol. Chem. 281: 35397-35403.
- Ataga, K.I., et al. 2007. β-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139: 3-13.
- Berger, A.C., et al. 2007. The subcellular localization of the Niemann-Pick Type C proteins depends on the adaptor complex AP-3. J. Cell. Sci. 120: 3640-3652.
- Lee, J.H. and Paull, T.T. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26: 7741-7748.
- 8. O'Connor, M.J., et al. 2007. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26: 7816-7824.
- Kaste, S.C., et al. 2008. Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr. Radiol. 38: 2-17.

CHROMOSOMAL LOCATION

Genetic locus: C11orf21 (human) mapping to 11p15.5.

SOURCE

C11orf21 (C-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of C11orf21 of human origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-241998 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

C11orf21 (C-15) is recommended for detection of C11orf21 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for C11orf21 siRNA (h): sc-96808, C11orf21 shRNA Plasmid (h): sc-96808-SH and C11orf21 shRNA (h) Lentiviral Particles: sc-96808-V.

Molecular Weight of C11orf21: 14 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**